Facing mounting pressure from competing therapies, Genentech has outlined plans to have 20 different drug development programs in place by 2008, with 50 different projects underway that would include plans to expand the use of drugs already approved for marketing. Avastin, for example, is in development for a number of new cancer indications. Genentech officials were putting their most ambitious face on their pipeline review as analysts have expressed concerns [1] about the company's ability to keep up its meteoric increase in revenue.

- here's the AP report [2] on Genentech's research plans

Related Articles:
Genentech fights to keep edge in drug development. Report [3]
Genentech hiring researchers in big R&D push. Report [4]
Genentech shifts its focus to immunology. Report [5]